Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $35.00.

A number of equities analysts recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Morgan Stanley dropped their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox sold 3,311 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $60,789.96. Following the sale, the chief executive officer directly owned 370,834 shares in the company, valued at approximately $6,808,512.24. This trade represents a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian S. Posner acquired 2,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was acquired at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the transaction, the director owned 24,500 shares in the company, valued at approximately $415,030. The trade was a 8.89% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently made changes to their positions in the company. Creative Planning lifted its position in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares during the period. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics during the 1st quarter valued at about $26,000. Caxton Associates LLP lifted its position in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 9.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock worth $315,000 after acquiring an additional 2,108 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $18.19 on Monday. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -5.65 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The stock’s 50-day simple moving average is $18.27 and its 200 day simple moving average is $18.15. Dyne Therapeutics has a 52-week low of $8.06 and a 52-week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) EPS. Research analysts forecast that Dyne Therapeutics will post -3 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.